Clarithromycin Ineffective for Coronary Heart Disease
FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.
FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.
Am Fam Physician. 2006 May 1;73(9):1620-1623.
Clinical Question: In patients with stable coronary heart disease, does clarithromycin (Biaxin) treatment decrease bad outcomes?
Setting: Outpatient (any)
Study Design: Randomized controlled trial (double-blinded)
Synopsis: Since Chlamydia pneumoniae has been isolated from atherosclerotic tissue, researchers have explored the use of antibiotic treatment of patients with coronary heart disease. Danish researchers identified all 13,702 patients in the Copenhagen, Denmark area diagnosed with myocardial infarction or angina pectoris, then randomized 4,373 of these patients, using concealed allocation, for this study. The patients were treated with oral clarithromycin 500 mg once daily or placebo for two weeks. Over an average of three years, the combined outcome of all-cause mortality or myocardial infarction was not different between the two groups (15.8 percent with clarithromycin versus 13.8 percent with placebo). However, the individual outcome of all-cause mortality was significantly higher in the antibiotic group (9.8 versus 7.8 percent; P = .03). This increase in the death rate was because of a significant increase in cardiovascular mortality (5.1 versus 3.5 percent; P = .01). In addition, adverse events were significantly more common in the pateints treated with clarithromycin.
Bottom Line: The theory of a bacterial cause of heart disease is rapidly deflating. Using the antibiotic clarithromycin in patients with coronary heart disease is not beneficial and may be harmful, with one additional death for every 50 patients who receive clarithromycin. Two other studies also have shown a slight increase in mortality with antibiotic therapy; taken together, these three studies show a 28 percent increase in mortality with clarithromycin (odds ratio = 1.28; 95% confidence interval, 1.05 to 1.57). (Level of Evidence: 1b)
Jespersen CM, et al., for the CLARICOR Trial Group. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial [Published correction appears in BMJ 2006;332:151] BMJ. January 7, 2006;332:22–7.
Used with permission from Shaughnessy AF. Clarithromycin ineffective in CHD. Accessed February 10, 2006, at: http://www.InfoPOEMs.com.
Want to use this article elsewhere? Get Permissions